GlassScriptPhysician profile
Gordon K Watson
NPI 1225031131
$9,984.63
in general payments reported to CMS, 2019-2025
32 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,406 · 2020: $370 · 2021: $1,273 · 2022: $1,510 · 2023: $2,337 · 2024: $1,772 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,425.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,677.21 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,159.95 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $787.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $748.66 | 2019-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $669.76 | 2022-2024 | Opsumit, Uptravi |
| Amgen INC. | $562.01 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $516.67 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $479.44 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $387.37 | 2021-2025 | Verquvo, Capvaxive |
| Impulse Dynamics (USA) INC. | $304.75 | 2022-2024 | Optimizer, Optimizer |
| Sanofi-Aventis U.S. LLC | $245.19 | 2019-2024 | |
| Edwards Lifesciences Corporation | $226.69 | 2023-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $222.62 | 2019-2025 | Wainua, Farxiga |
| Abbott Laboratories | $220.99 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $214.84 | 2019-2025 | Eliquis, Camzyos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $163.19 | 2019 | |
| Alnylam Pharmaceuticals INC. | $160.92 | 2022-2025 | Amvuttra |
| Cvrx, INC. | $150.43 | 2024-2025 | Barostim Neo System |
| Philips North America LLC | $130.75 | 2019 | |
| Amarin Pharma, INC. | $118.41 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $105.32 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $103.19 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $100.92 | 2021-2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $100.32 | 2025 | Assure Wcd |
| Bardy Diagnostics, INC. | $80.00 | 2019-2020 | |
| Esperion Therapeutics, INC. | $72.03 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.82 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $55.04 | 2024 | Arcalyst |
| Novo Nordisk INC | $48.72 | 2024-2025 | Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $45.29 | 2025 | |
| Bridgebio Pharma, INC. | $41.98 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.